Abstract
We have witnessed an explosion of developments in the field of inflammatory arthritis over the last few years. For example, advances in our understanding of disease pathogenesis have resulted in therapies that can target specific disease related inflammatory cytokines leading to improved clinical outcomes. Much of this research has been in rheumatoid arthritis (RA), but new treatments have also been successfully translated into benefits for patients with other rheumatic diseases. This article focuses on a selection of the current developments as they move into routine clinical practise and will discuss: the use of anti TNFα therapies and other ‘biological agents’ in inflammatory joint disease; advances in musculoskeletal imaging with magnetic resonance imaging (MRI) and ultrasound; the diagnosis and treatment of early inflammatory arthritis; the impact of systemic inflammatory disease on cardiovascular mortality; the treatment of psoriatic arthritis; the use of potent intravenous bisphosphonates for bone disease and the increasing incidence of gout. We have witnessed an explosion of developments in the field of inflammatory arthritis over the last few years. For example, advances in our understanding of disease pathogenesis have resulted in therapies that can target specific disease related inflammatory cytokines leading to improved clinical outcomes. Much of this research has been in rheumatoid arthritis (RA), but new treatments have also been successfully translated into benefits for patients with other rheumatic diseases. This article focuses on a selection of the current developments as they move into routine clinical practise and will discuss: the use of anti TNFα therapies and other ‘biological agents’ in inflammatory joint disease; advances in musculoskeletal imaging with magnetic resonance imaging (MRI) and ultrasound; the diagnosis and treatment of early inflammatory arthritis; the impact of systemic inflammatory disease on cardiovascular mortality; the treatment of psoriatic arthritis; the use of potent intravenous bisphosphonates for bone disease and the increasing incidence of gout.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.